DOCSLIB.ORG

Commercializing the New Biology: a Tribute to Ronald E. Cape

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SIMB MolecularPioneering NewsResearch CEO News magazine of the Society for Industrial BiochemistMicrobiologyUniversity and Biotechnology DNAV N October/November/DecemberPolymerase 2019 .69 .4 • www.simbhq.orgBusinessScientific Entrepreneurial Industry Corporation FounderCommercializing Interferon Constellation Genethe New Biology: ApplicationChairman A Tribute to Patent Pharmaceutical PCR Recombinant BreakthroughDiagnostic Cloning RonaldVenture E. Cape Leadership Cetus Biotechnology2020 Election PresidentInterleukinfor Board of DirectorsBusinessman Call for SIMB Award 4 . .69 2019 October/November/December N V Nominations Journal of Industrial Microbiology & Biotechnology Impact Factor 2.993 The Journal of Industrial Microbiology and Biotechnology is an international journal which publishes papers in all areas of applied microbiology, e.g., biotechnology, fermentation and cell culture, biocatalysis, environmental microbiology, natural products discovery and biosynthesis, metabolic engineering, genomics, bioinformatics, food microbiology. Editor-in-Chief • Ramon Gonzalez, Rice University, Houston, TX, USA Special Issue Natural Product Discovery and Editors Development in the Genomic Era; Mar. 2019 • S. Bagley, Michigan Tech, Houghton, MI, USA • R. H. Baltz, CognoGen Biotech. Consult., Sarasota, FL, USA • T. W. Jeffries, University of Wisconsin, Madison, WI, USA • T. D. Leathers, USDA ARS, Peoria, IL, USA • M. J. López López, University of Almeria, Almeria, Spain • C. D. Maranas, Pennsylvania State Univ., Univ. Park, PA, USA • S. Park, UNIST, Ulsan, Korea • J. L. Revuelta, University of Salamanca, Salamanca, Spain • B. Shen, Scripps Research Institute, Jupiter, FL, USA • D. K. Solaiman, USDA ARS, Wyndmoor, PA, USA • Y. Tang, University of California, Los Angeles, CA, USA • E. J. Vandamme, Ghent University, Ghent, Belgium • J. Yang, Amgen Inc., Oak Park, CA, USA • H. Zhao, University of Illinois, Urbana, IL, USA 5 Most Cited Articles of JIMB in 2018: Authors Title Year Cites Katz, Leonard; Baltz, Richard H. Natural product discovery: past, present, and future 2016 63 Multiplex gene editing of the Yarrowia lipolytica genome using the CRISPR-Cas9 Gao, Shuliang, et al. 2016 26 system Genetic manipulation of secondary metabolite biosynthesis for improved Baltz, Richard H. 2016 23 production in Streptomyces and other actinomycetes Baltz, Richard H. Gifted microbes for genome mining and natural product discovery 2017 20 Katz, Micah; Hover, Bradley Culture-independent discovery of natural products from soil metagenomes 2017 15 M.; Brady, Sean F. Submission information Electronic access ▶ ww.springer.com/10295 ▶ link.springer.com/journal/10295 contents news 114 NEWSWORTHY SIMB News Melanie Mormile | Editor-in-Chief 116 IN MEMORIAM: JEAN BRENCHLEY Elisabeth Elder | Associate Editor Stephanie Gleason | Associate Editor feature Kristien Mortelmans | Associate Editor COMMERCIALIZING THE NEW BIOLOGY: Vanessa Nepomuceno | Associate Editor 118 A TRIBUTE TO RONALD E. CAPE DESIGN & PRODUCTION Katherine Devins | Production Manager meetings 125 NATURAL PRODUCTS 2020 BOARD OF DIRECTORS 127 SBFC 2020 President Jan Westpheling 128 SIMB ANNUAL MEETING 2020 President-Elect Steve Decker 129 INDUSTRIAL MICROBIOLOGY MEETS MICROBIOME (IMMM) 2020 Past President Steve Van Dien Secretary Elisabeth Elder members Treasurer Laura Jarboe 134 LETTER FROM THE SIMB PRESIDENT Directors Katy Kao SOCIETY RESOLUTIONS Priti Pharyka 135 Tiffany Rau 138 CALL FOR AWARD NOMINATIONS Michael Resch 139 NEW BOARD OF DIRECTORS HEADQUARTERS STAFF 140 SIMB ELECTION 2020 Christine Lowe | Executive Director Jennifer Johnson | Director of Member Services book review Tina Hockaday | Meeting Coordinator Suzannah Citrenbaum | Web Manager 132 THE POISON SQUAD Esperanza Montesa | Accountant in every issue EDITORIAL CORRESPONDENCE CORPORATE MEMBERS Melanie R. Mormile 110 Email: [email protected] 111 LETTER FROM THE EDITOR-IN-CHIEF 133 SIMB STRATEGIC PLAN ADVERTISING For information regarding rates, contact 147 CALENDAR OF EVENTS SIMB News 150 SIMB CORPORATE MEMBERSHIP APPLICATION 3929 Old Lee Highway, Suite 92A Fairfax, VA 22030-2421 P: 703-691-3357 ext 30 F:703-691-7991 Email: [email protected] www.simbhq.org SIMB News (ISSN 1043-4976), is published On the cover quarterly, one volume per year, by the Word map Society for Industrial Microbiology and Biotechnology and is provided to all SIMB MolecularPioneering members. Research CEO POSTMASTER: Send address changes to CONTACT SIMB DNABiochemistUniversity (703) 691-3357 SIMB News, 3929 Old Lee Highway, Suite 92A, Polymerase BusinessScientific Entrepreneurial Fairfax, VA 22030-2421 Industry Corporation Executive Director Founder Christine Lowe, Ext. 26 Copyright © 2019, Society for Industrial Interferon Constellation Microbiology and Biotechnology. Director of Member Services Gene Jennifer Johnson, Ext. 23 All rights reserved. ApplicationChairman Patent Meeting Coordinator Pharmaceutical PCR Recombinant Tina Hockaday, Ext. 24 BreakthroughDiagnostic Cloning Venture Web Manager Leadership Cetus Suzannah Citrenbaum, Ext. 27 Biotechnology Accountant PresidentInterleukin Businessman Esperanza Montesa, Ext. 22 October • November • December 2019 SIMB NEWS 109 corporate members Diamond Members Silver Members ICM, Inc. Applikon Biotechnology, Inc. Kuhner Shaker, Inc. Corteva Agriscience Novozymes, Inc. Envera, LLC Sartorius Stedium Biotech Eppendorf Gold Members Gardner Industries, Inc. Global Bioingredients, Inc. DCI-Biolafitte KATZEN International, Inc. Flownamics Lallemand, Inc. Genesis Biosciences, Inc. Moubio, LLC Hamilton Company Mycosynthetix, Inc. INFORS USA Panlabs Biologics, Inc. m2P Labs, Inc. Tatua USA Ltd. Marcor, an Azelis company Traders Protein Procelys Xylome Sensient Global Bionutrients Bronze Members BioIntelligence Technologies Pneumatic Scale Angelus Institutional Members ERWAT Golden Leaf Biomanufacturing Training and Education Center - North Carolina State University 110 SIMB NEWS www.simbhq.org editor's corner Letter from the Editor-in-Chief The end of the calendar year always brings one to reflect on what has occurred in the past and an anticipation for what will come in the new year. The current issue of SIMB News certainly suits this condition. In remembrance, the feature article provides an overview of the great impact that Ronald E. Cape had on the development of the field of biotechnology and industrial microbiology. Jean E. Brenchley is also remembered for her contributions to the field of biotechnology and her impact at Pennsylvania State University. Resolutions marking the achievements of the Society for Industrial Microbiology and Biotechnology over the past year are also provided. With an eye towards the future, the Society’s Strategic Plan is included in this issue. For the Society to fulfill its Plan, the participation of the Society’s membership is required. One critical way that all members can be active participants in the Society is to vote in the upcoming election for President, Treasurer, and Board of Directors. Be sure to carefully read the biographies of all the candidates, make your decisions for each position, and vote! In addition to voting, there are conferences being held throughout 2020 that will appeal to all members. Be sure to attend at least one conference and participate as fully as you are able. In closing, I hope that 2020 will be a successful and enjoyable year for you! Sincerely, Melanie R. Mormile Editor-in-Chief, SIMB News [email protected] October • November • December 2019 SIMB NEWS 111 SAVE THE DATE Industrial Microbiology Meets Microbiome (IMMM) 2020 San Diego, CA November 8–10, 2020 www.simbhq.org/immm TIME TO RENEW! Individual and corporate membership renewals for 2020 are due! Visit www.simbhq.org to renew today. news Newsworthy Organizations Urge Federal Agencies to Balance Security Considerations with Impacts on Scientific Collaborations In a September 4, 2019 letter, sixty science, engineering, and international education organizations, have urged the heads of the White House Office of Science and Technology Policy (OSTP), the National Science Foundation (NSF), the National Institutes of Health (NIH), the Department of Energy (DOE), and the Department of Defense (DOD) to consider a wide range of stakeholder perspectives as the agencies work together to address issues of foreign influence on U.S. research. The letter reads, “While we must be vigilant to safeguard research, we must also ensure that the U.S. remains a desirable and welcoming destination for researchers from around the world. Finding the appropriate balance between our nation’s security and an open, collaborative scientific environment requires focus and due diligence.” The agencies have been tasked with working together through the new National Science and Technology Council (NSTC) Joint Committee on Research Environments to develop policies and procedures that address issues related to the participation of international researchers in the U.S. scientific enterprise. The letter warns about a rising concern among U.S. and international scientists that “new policies and procedures under consideration to minimize security risks will have the unintended effect of harming the scientific enterprise.” 114 SIMB NEWS www.simbhq.org news Newsworthy NSB Calls for Growing the Skilled Technical Workforce The National Science Board (NSB) — the governing body for the National Science Foundation (NSF) — has released a new report titled, “The Skilled Technical Workforce: Crafting America’s Science and Engineering Enterprise.”
Recommended publications
  • Novartis / Chiron Regulation (Ec)

    Novartis / Chiron Regulation (Ec)

    EN Case No COMP/M.4049 - NOVARTIS / CHIRON Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 06/02/2006 In electronic form on the EUR-Lex website under document number 32006M4049 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 06-02-2006 SG-Greffe (2006) D/200529 In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and PUBLIC VERSION other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a MERGER PROCEDURE general description. ARTICLE 6(1)(b) DECISION To the notifying party Dear Madam/Sir, Subject: Case No. COMP/M.4049 – Novartis / Chiron Notification of 23/12/2005 pursuant to Article 4 of Council Regulation No 139/20041 (“Merger Regulation”) 1. On 23/12/2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Novartis AG (“Novartis”, Switzerland) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Chiron Corporation (“Chiron”, United States) by way of purchase of shares. 2. After examination of the notification, the Commission has concluded that the notified operation constitutes a concentration that falls within the scope of the Merger Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA Agreement.
  • Documenting the Biotechnology Industry in the San Francisco Bay Area

    Documenting the Biotechnology Industry in the San Francisco Bay Area

    UC San Diego Reports and Studies Title Documenting the Biotechnology Industry in the San Francisco Bay Area Permalink https://escholarship.org/uc/item/1m24k447 Author Chandler, Robin L. Publication Date 1997 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Documenting the Biotechnology Industry In the San Francisco Bay Area Robin L. Chandler Head, Archives and Special Collections UCSF Library and Center for Knowledge Management 1997 1 Table of Contents Project Goals……………………………………………………………………….p. 3 Participants Interviewed………………………………………………………….p. 4 I. Documenting Biotechnology in the San Francisco Bay Area……………..p. 5 The Emergence of An Industry Developments at the University of California since the mid-1970s Developments in Biotech Companies since mid-1970s Collaborations between Universities and Biotech Companies University Training Programs Preparing Students for Careers in the Biotechnology Industry II. Appraisal Guidelines for Records Generated by Scientists in the University and the Biotechnology Industry………………………. p. 33 Why Preserve the Records of Biotechnology? Research Records to Preserve Records Management at the University of California Records Keeping at Biotech Companies III. Collecting and Preserving Records in Biotechnology…………………….p. 48 Potential Users of Biotechnology Archives Approaches to Documenting the Field of Biotechnology Project Recommendations 2 Project Goals The University of California, San Francisco (UCSF) Library & Center for Knowledge Management and the Bancroft Library at the University of California, Berkeley (UCB) are collaborating in a year-long project beginning in December 1996 to document the impact of biotechnology in the Bay Area. The collaborative effort is focused upon the development of an archival collecting model for the field of biotechnology to acquire original papers, manuscripts and records from selected individuals, organizations and corporations as well as coordinating with the effort to capture oral history interviews with many biotechnology pioneers.
  • History of Digital PCR Trisha Dhawan and Rémi Dangla 8/8/19

    History of Digital PCR Trisha Dhawan and Rémi Dangla 8/8/19

    History of Digital PCR Trisha Dhawan and Rémi Dangla 8/8/19 Outline 1.1. PCR, the start of a revolution .......................................................................................... 1 1.2. Limit dilution PCR .......................................................................................................... 1 1.3. Digital PCR, a term coined by Vogestein and Kinzler ................................................... 2 2.1. PCR meets microfluidics ................................................................................................ 2 2.2. PCR in micro-droplets .................................................................................................... 3 3.1. Digital PCR in Microarrays ............................................................................................ 4 3.2. Digital PCR in Micro-droplets ........................................................................................ 4 Combining microarrays and microdropelts with Crystal™ digital PCR ............................ 5 Discussion ........................................................................................................................... 6 The origins of Digital PCR of template nucleic acid molecules, oligonucleotide primers, dNTPs, and a 1.1. PCR, the start of a revolution thermostable DNA polymerase. Over the years, The polymerase chain reaction (PCR) was ongoing development and application of the PCR invented by Kary Mulis while he was developing reaction enabled molecular cloning, engineered methods for
  • Regional Oral History Office University of California the Bancroft Library Berkeley, California

    Regional Oral History Office University of California the Bancroft Library Berkeley, California

    Regional Oral History Office University of California The Bancroft Library Berkeley, California Program in Bioscience and Biotechnology Studies RONALD E. CAPE, M.B.A., Ph. D. BIOTECH PIONEER AND CO-FOUNDER OF CETUS Interviews Conducted by Sally Smith Hughes in 2003 Copyright © 2006 by The Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of northern California, the West, and the nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. ************************************ All uses of this manuscript are covered by legal agreements between The Regents of the University of California and Ronald Cape, dated December 18, 2003. The manuscript is thereby made available for research purposes. All literary rights in the manuscript, including the right to publish, are reserved to The Bancroft Library of the University of California, Berkeley.
  • Documenting the Biotechnology Industry in the San Francisco Bay Area

    Documenting the Biotechnology Industry in the San Francisco Bay Area

    Documenting the Biotechnology Industry In the San Francisco Bay Area Robin L. Chandler Head, Archives and Special Collections UCSF Library and Center for Knowledge Management 1997 1 Table of Contents Project Goals……………………………………………………………………….p. 3 Participants Interviewed………………………………………………………….p. 4 I. Documenting Biotechnology in the San Francisco Bay Area……………..p. 5 The Emergence of An Industry Developments at the University of California since the mid-1970s Developments in Biotech Companies since mid-1970s Collaborations between Universities and Biotech Companies University Training Programs Preparing Students for Careers in the Biotechnology Industry II. Appraisal Guidelines for Records Generated by Scientists in the University and the Biotechnology Industry………………………. p. 33 Why Preserve the Records of Biotechnology? Research Records to Preserve Records Management at the University of California Records Keeping at Biotech Companies III. Collecting and Preserving Records in Biotechnology…………………….p. 48 Potential Users of Biotechnology Archives Approaches to Documenting the Field of Biotechnology Project Recommendations 2 Project Goals The University of California, San Francisco (UCSF) Library & Center for Knowledge Management and the Bancroft Library at the University of California, Berkeley (UCB) are collaborating in a year-long project beginning in December 1996 to document the impact of biotechnology in the Bay Area. The collaborative effort is focused upon the development of an archival collecting model for the field of biotechnology to acquire original papers, manuscripts and records from selected individuals, organizations and corporations as well as coordinating with the effort to capture oral history interviews with many biotechnology pioneers. This project combines the strengths of the existing UCSF Biotechnology Archives and the UCB Program in the History of the Biological Sciences and Biotechnology and will contribute to an overall picture of the growth and impact of biotechnology in the Bay Area.
  • Richard Gregory, Et Al. V. Chiron Corporation, Et Al. 04-CV-04293-Request for Judicial Notice in Support of Chiron Corporation&

    Richard Gregory, Et Al. V. Chiron Corporation, Et Al. 04-CV-04293-Request for Judicial Notice in Support of Chiron Corporation&

    EXHIBIT F Chiron News Page 1 of 9 Lc Chiron Reports 2003 Second -Quarter Pro-Forma Income of 35 Cents Per Share 17 Percent Increase in Revenues Over 200 2 EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq : CHIR) today reported pro-forma income from continuing operations of $67 million, or $0 .35 per share, for the second quarter of 2003, compared to $56 million, or $0.29 per share, for the second quarter of 2002 . (Chiron management uses pro-forma financial statements to gain an understanding of the company's operating performance on a comparative basis . Pro-forma results exclude special items relating to certain acquisitions and revenues, which may not be relevant to gaining an understanding of the company's trends or potential future performance . Please refer to the attached tables at the end of this document for more detail on these items and a reconciliation to GAAP financial statements .) On a GAAP basis, Chiron's income from continuing operations was $61 million, or $0 .32 per share, for the second quarter of 2003, compared to $50 million, or $0 .26 per share, for the second quarter of 2002 . (All references to per-share amounts are per diluted share .) Foreign exchange rates, on a pro-forma basis, resulted in a $0 .01 increase in earnings per share . "Chiron made several important advances that demonstrate our momentum as a global biopharmaceutical company and that will help drive growth from the immediate to the long term, increasing shareholder value," said Howard Pion, Chiron's president and CEO . "Prominent among these was our acquisition of PowderJect, which makes us the second-largest flu vaccines manufacturer worldwide and adds a U .S.
  • Spare the Air Employer Program Members

    Spare the Air Employer Program Members

    Spare the Air Employer Program Members 511 Affymetrix Inc. 1000 Journals Project Agilent Technologies ‐ Sonoma County 3Com Corporation Public Affairs 511 Contra Costa Agnews Developmental Center 511 Regional Rideshare Program AHDD Architecture 7‐Flags Car Wash Air Products and Chemicals, Inc. A&D Christopher Ranch Air Systems Inc. A9.com Akeena Solar AB & I Akira ABA Staffing, Inc. Akraya Inc. ABB Systems Control Alameda Co. Health Care for the Homeless Abgenix, Inc. Program ABM Industries, Inc Alameda County Waste Management Auth. Above Telecommunications, Inc. Alameda Free Library Absolute Center Alameda Hospital AC Transit Alameda Unified School District Academy of Art University Alder & Colvin Academy of Chinese Culture & Health Alexa Internet Acclaim Print & Copy Centers Allergy Medical Group Of S F A Accolo Alliance Credit Union Accretive Solutions Alliance Occupational Medicine ACF Components Allied Waste Services/Republic Services Acologix Inc. Allison & Partners ACRT, Inc Alta Bates/Summit Medical Center ACS State & Local Solutions Alter Eco Act Now Alter Eco Americas Acterra ALTRANS TMA, Inc Actify, Inc. Alum Rock Library Adaptive Planning Alza Corporation Addis Creson American Century Investment Adina for Life, Inc. American International (Group) Companies Adler & Colvin American Lithographers ADP ‐ Automatic Data Processing American Lung Association Advance Design Consultants, Inc. American Musical Theatre of San Jose Advance Health Center American President Lines Ltd Advance Orthopaedics Amgen, Inc Advanced Fibre Communications Amtrak Advanced Hyperbaric Recovery of Marin Amy’s Kitchen Advanced Micro Devices, Inc. Ananda Skin Spa Advantage Sales & Marketing Anderson Zeigler Disharoon Gallagher & Advent Software, Inc Gray Aerofund Financial Svcs.,Inc. Anixter Inc. Affordable Housing Associates Anomaly Design Affymax Research Institute Anritsu Corporation Anshen + Allen, Architects BabyCenter.com Antenna Group Inc BACE Geotechnical Anza Library BackFlip APEX Wellness Bacon's Applied Biosystems BAE Systems Applied Materials, Inc.
  • The New Eppendorf Micro Centrifuge

    The New Eppendorf Micro Centrifuge

    The new Eppendorf Micro Centrifuge. • With 50% higher::capacity,: variable speed,. quieter operation, and .......... Brand ...: .......... Higher capacity..,plus. Safe and ru ggecJ. The new..1.8-place. Model 5415 The" Eppe~dorf 5415 Micro Micro Centrifuge g wes you Centrifuge is UL listed for ~.i.mportant operating advantages-- • . safety: It's sorugged th.atan with unique Eppendorf quality: : acci.den~tatlyiunbalanced 4oad ......... Enclosed rotor design reduces air.turbulence won't cause excessive vibration Versatile in use, and noise. Tubes are angled precisely at 45°.to 0rm0tof~ damage. M.odel.5415 has a variable-speed maximize pellet formation. For more information:: call " ' ~ : " motor that reaches a maximum 800~645-3050;. in NewYork., . of.14,000 rpm with anlRCF of 5164334.~7500.,:. Or write . 16,000 x g;. a 30-minute:timer; Brinkmann..Ins.truments, Inc., • and a momentary button for short Cantiague Road,. Westbury, spins. It accepts 1.5 mL,.500 t~L, NY 11590. (In Canada ................... 400 I~L, and 250 #L Eppendorf 416-~675W911; 50 Galaxy Blvd., •Microcentrifuge Tubes and Rexdale., Ont. M9W 4Y5) blood Collection microtubes, such as B-D Microtainer*Tubes. Specifications ......... Maximumspeed: l4,000i;pm " New rotor design. Maximum RCF ...... : 16.000 x g The enclosedrotor design Test-tube capacity ':: 1:.8 ...... reduces air turbulencefor Timerequired for " - " maximum speed i....10.sec. quieter operation:. And the new Timerequired to stop I~2 sec ........ - Quick, release feature; aitowsthe18-position :.Dimensions quick,reie.ase featu re lets.you rotor to be easily transported even.when ....... (L X W x H): 28 X 2! x 28.5 cm transport the: rotor with tubes--- Loaded .....
  • Henry A. Erlich EDITOR

    Henry A. Erlich EDITOR

    Principles and Applications for DNA Amplification Henry A. Erlich EDITOR M stockton press New York London Tokyo Melbourne Hong Kong For Brenda and Justin ©Stockton Press, 1989 All rights reserved. No part of this publication may be reproduced, or transmitted, in any form or by any means, without permission. Published in the United States and Canada by Stockton Press, 1989 15 East 26th Street, New York, N.Y. 10010 Library of Congress Cataloging-in-Publication Data PCR technology. (Breakthroughs in molecular biology) 1. DNA polymerases. 2. DNA-Synthesis. 3. DNA polymerases-Biotechnology. I. Erlich, Henry A., 1943- . II. Series. [DNLM: I. DNAPolymerases. 2. Gene Amplification. 3. Genetic Engineering. 4. Molecular Biology. 5. RNA Polymerases. QH442P348] QP606.D64P37 1989 574.87'3282 89-4342 ISBN 978-0-935859-56-X (pbk.) Published in the United Kingdom by MACMILLAN PUBLISHERS LTD (Journals Division), 1989 Distributed by Globe Book Services Ltd, Brunei Road, Houndmills, Basingstoke, Hants RG21 2XS, England British Library Cataloguing in Publication Data Erlich, Henry DNA amplification using the PCR 1. Organisms. DNA polymerases I. Title 574.87'3282 ISBN 978-0-333-48948-2 ISBN 978-1-349-20235-5 (eBook) DOI 10.1007/978-1-349-20235-5 98765432 PREFACE Since the ftrst report of specific DNA amplification using the polymerase chain reaction (PCR) in 1985, the number of different applications has grown steadily, as have the modifications of the basic method. This increase has been claimed to be exponential - like the PCR itself. In any case, detailed discussion of the full range of biological problems under investigation as well as all of the various experimental approaches utilizing PCR is beyond the scope of this book.
  • Growth and Urban Redevelopment in Emeryville

    Growth and Urban Redevelopment in Emeryville

    Growth and Urban Redevelopment in Emeryville East Bay Alliance for a Sustainable Economy Center for Labor Research and Education University of California, Berkeley A Publication of the California Partnership for Working Families May 2003 Growth and Urban Redevelopment in Emeryville East Bay Alliance for a Sustainable Economy Center for Labor Research and Education University of California, Berkeley Howard Greenwich Elizabeth Hinckle May 2003 A Publication of the California Partnership for Working Families East Bay Alliance for a Sustainable Economy, Oakland, CA Center on Policy Initiatives, San Diego, CA Los Angeles Alliance for a New Economy, CA Working Partnerships USA, San Jose, CA BEHIND THE BOOMTOWN ACKNOWLEDGEMENTS AND CREDITS This report was prepared by EBASE with the generous support of many individuals and organizations. We are indebted to the community members, workers, city representatives, and businesses of Emeryville for their time and insights into the transfor- mation of their city. We would like to thank: community members Angel Norris, Gladys Vance, Jim Martin, Barbara MacQuiddy, Gisele Wolf, Mary McGruder, Russell Moran, Bridget Burch, and Deloris Prince; store managers Al Kruger, Renee Conse, Sam Combs, Carlos Torres, and Chuck Pacioni; developers Pat Cashman, Shi-Tso Chen, Eric Hohmann, Glenn Isaacson, and Steven Meckfessel; businesspersons Bob Cantor and Jay Grover; current and former city staff members Ignacio Dayrit, Ron Gerber, Ellen Whitton, Pauline Marx, Karan Reid, Autumn Buss, Patrick O’Keeffe, Jeannie Wong, Wendy Silvani and Rebecca Atkinson; former City Councilmembers and Planning Commissioners Stu Flashman, Andy Getz and Greg Harper; current City Councilmembers Ruth Atkin and Nora Davis; and from the Emery Unified School District, State Administrator Henry Der and Advisory Board President Forrest Gee.
  • Site Cleanup Plan

    Site Cleanup Plan

    SITE CLEANUP PLAN Horton Landing Park Emeryville, California EPA Project No. BF-96921301 March 2010 Prepared for: City of Emeryville Redevelopment Agency 1333 Park Avenue Emeryville, California SITE CLEANUP PLAN Horton Landing Park Emeryville, California EPA Project No. BF-96921301 March 2010 Prepared for: City of Emeryville Redevelopment Agency 1333 Park Avenue Emeryville, California Prepared by: Erler & Kalinowski, Inc. 1870 Ogden Drive Burlingame, California EKI A90007.00 Erler & Kalinowski, Inc. Consulting Engineers and Scientists 1870 Ogden Drive Burlingame, CA 94010 (650) 292-9100 Fax: (650) 552-9012 5 March 2010 Ms. Karen Toth California Environmental Protection Agency Department of Toxic Substances Control 700 Heinz Avenue Suite 200 Berkeley, California 94710 SUBJECT: Site Cleanup Plan Horton Landing Park, Emeryville, California (EKI A90007.00) Dear Ms. Toth: Erler & Kalinowski, Inc. (“EKI”) is pleased to present this Site Cleanup Plan (“SCP”) for the Horton Landing Park property (“Site”), located in Emeryville, California. This report is being submitted on behalf of our client, the City of Emeryville Redevelopment Agency (“Agency”). This SCP describes the nature and extent of contamination at the Site, remedial action objectives (“RAOs”), and selected Site-specific cleanup goals to meet RAOs, includes a description and comparison of cleanup alternatives, and recommends a cleanup alternative for the Site. This SCP incorporates DTSC comments on the Draft Site Cleanup Plan, dated November 2009 provided by email on 1 December 2009. Included in this SCP are plans that describe the procedures required in order to implement the proposed remedial alternative. These plans serve to provide guidance for health and safety measures to be employed during soil remedial activities.
  • Annual Report 1998 Expertise with Responsibility

    Annual Report 1998 Expertise with Responsibility

    Annual Report 1998 Expertise with Responsibility Bayer is a diversified, international chemicals and health care group. We offer our customers a wide variety of products and services in areas ranging from pharmaceuticals and crop protection to plastics, specialty chemicals and imaging technologies. Bayer is research-based and aims for technological leadership in its core activities. Our goals are to steadily increase corporate value and generate a high value added for the benefit of our stockholders, our employees and the community in every country in which we operate. We believe that our technical and commercial expertise involves a responsibility to work for the common good and contribute to sustainable development. Bayer: Success through Expertise with Responsibility. Bayer Key Data Bayer Group 1998 1997 Change in % Sales DM million 54,884 55,005 – 0.2 Operating result DM million 6,151 6,018 + 2.2 Income before income taxes DM million 5,336 5,108 + 4.5 Net income DM million 3,157 2,941 + 7.3 Gross cash flow DM million 6,602 6,480 + 1.9 Stockholders’ equity DM million 24,991 23,923 + 4.5 Total assets DM million 57,216 54,170 + 5.6 Capital expenditures DM million 5,165 4,559 + 13.3 Employees at year end 145,100 144,600 + 0.3 Personnel expenses DM million 15,854 15,442 + 2.7 Research and development expenses DM million 3,920 3,878 + 1.1 Bayer AG 1998 1997 Change in % Total dividend payment DM million 1,461 1,388 + 5.3 Dividend per share DM 2.00 1.90 + 5.3 Tax credit DM 0.65 0.81 - 19.8 Published by Bayer AG, 51368 Leverkusen, This complete version of the Annual Report Germany is published in English and German.